Bisorcic

Bisorcic
Clinical data
Other namesN2,N5-Diacetyl-L-ornithine; N2,N5-Diacetylornithine; Nα,Nδ-Diacetylornithine
Routes of
administration		Oral
Drug classHepatoprotective agent; Psychostimulant
Identifiers
  • (2S)-2,5-diacetamidopentanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.049.659 Edit this at Wikidata
Chemical and physical data
FormulaC9H16N2O4
Molar mass216.237 g·mol−1
3D model (JSmol)
  • CC(=O)NCCC[C@@H](C(=O)O)NC(=O)C
  • InChI=1S/C9H16N2O4/c1-6(12)10-5-3-4-8(9(14)15)11-7(2)13/h8H,3-5H2,1-2H3,(H,10,12)(H,11,13)(H,14,15)/t8-/m0/s1
  • Key:XUYANFPPYJSBPU-QMMMGPOBSA-N

Bisorcic (INNTooltip International Nonproprietary Name), also known as N2,N5-diacetyl-L-ornithine, is a drug described as a hepatoprotective agent and "psychostimulant" which has been used in France in the treatment of asthenia. It is the N2,N5-diacetylated derivative of the amino acid L-ornithine.

Bisorcic was first described in the literature in 1973 in a German patent. The INNTooltip International Nonproprietary Name was designated around 1975. The drug was marketed in France by Astyl-Gallier in 1987. It was provided in the form of 200 mg oral capsules and four capsules were taken daily.

L-Ornithine, as the combination drug L-ornithine L-aspartate (LOLA), has been used in the treatment of hepatic encephalopathy and cirrhosis and is likewise described as hepatoprotective. It is thought to work by participating in the urea cycle and lowering ammonia levels.

References

  1. 1 2 3 4 5 Schlesser JL (1990). Drugs Available Abroad: A Guide to Therapeutic Drugs Available and Approved for Use Outside the U. S. Gale Research; Derwent Publications Ltd. p. 24. ISBN 978-0-8103-7177-4. Retrieved 28 September 2024. 109 BISORCIC. Countries Where Available and Release Dates: France (1987). Brand Names and Manufacturers: Astyl-Gallier (France). Drug Action: Psychostimulant. Indications/Usage: Asthenia. How Supplied: 200 mg capsules. Dosage: 4 capsules daily. Not recommended in children. Contraindications: Epilepsy.
  2. 1 2 3 Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 906. ISBN 978-1-4757-2085-3. Retrieved 28 September 2024. Nα,Nδ-Di-Ac: [39825-23-5]. N2,N5-Diacetylornithine, 9Cl. Bisorcic, INN. 69H16N2O4. M 216,236. Hepatoprotective agent, psychostimulant. [...] Ger. Pat., 2 219 874, (1973); CA, 78, 98010t (Bisorcic).
  3. ↑ Buckingham J (2020). Dictionary of Natural Products. CRC Press. p. 356. ISBN 978-1-000-15302-6. Retrieved 28 September 2024.
  4. ↑ Blunt JW, Munro MH (2007). Dictionary of Marine Natural Products with CD-ROM. CRC Press. p. 522. ISBN 978-0-8493-8217-8. Retrieved 28 September 2024.
  5. ↑ Negwer M (1994). Organic-chemical Drugs and Their Synonyms: (an International Survey). Akademie Verlag. p. 359. ISBN 978-3-05-500156-7. Retrieved 28 September 2024. 6220. 39825-23-5 CI CI -NH2 N C10H10CI2N2O2 51 230-28-5. N2,N5-Diacetyl-L-ornithine. R see also no. 3704. S Bisorcic**. U Psychostimulant.
  6. ↑ "Bisorcic". PubChem. U.S. National Library of Medicine. Retrieved 28 September 2024.
  7. ↑ "Proposed International Nonproprietary Names (Prop. INN): List 34. International Nonproprietary Names for Pharmaceutical Substances" (PDF). Supplement to WHO Chronicle. 29 (9). 1975. Retrieved 28 September 2024.
  8. 1 2 Kircheis G, Lüth S (February 2019). "Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy". Drugs. 79 (Suppl 1): 23–29. doi:10.1007/s40265-018-1023-2. PMC 6416235. PMID 30706424.
  9. 1 2 Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY (May 2018). "L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis". The Cochrane Database of Systematic Reviews. 5 (5) CD012410. doi:10.1002/14651858.CD012410.pub2. PMC 6494563. PMID 29762873.